Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 11/2023

01-11-2023 | Metastasis | Review Article

Theranostic signature of tumor-derived exosomes in cancer

Authors: Samruti Kumar, Rajib Dhar, Lokesh Babu Sirkali Suresh Kumar, Gauresh Gurudas Shivji, Rama Jayaraj, Arikketh Devi

Published in: Medical Oncology | Issue 11/2023

Login to get access

Abstract

Cancer is the most challenging global health crisis. In the recent times, studies on extracellular vesicles (EVs) are adding a new chapter to cancer research and reports on EVs explores cancer in a new dimension. Exosomes are a group of subpopulations of EVs. It originates from the endosomes and carries biologically active molecules to the neighboring cells which in turn transforms the recipient cell activity. In general, it plays a role in cellular communication. The correlation between exosomes and cancer is fascinating. Tumor-derived exosomes (TEXs) play a dynamic role in cancer progression and are associated with uncontrolled cell growth, angiogenesis, immune suppression, and metastasis. Its molecular cargo is an excellent source of cancer biomarkers. Several advanced molecular profiling approaches assist in exploring the TEXs in depth. This paves the way for a strong foundation for identifying and detecting more specific and efficient biomarkers. TEXs are also gaining importance in scientific society for its role in cancer therapy and several clinical trials based on TEXs is a proof of its significance. In this review, we have highlighted the role of TEXs in mediating immune cell reprogramming, cancer development, metastasis, EMT, organ-specific metastasis, and its clinical significance in cancer theranostics. TEXs profiling is an effective method to understand the complications associated with cancer leading to good health and well-being of the individual and society as a whole.

Graphical abstract

Literature
1.
2.
3.
Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–79.PubMedCrossRef
4.
5.
Baig MS, et al. Tumor-derived exosomes in the regulation of macrophage polarization. Inflamm Res. 2020;69(5):435–51.PubMedCrossRef
6.
7.
Ghosh, S., et al., Clinical impact of exosomes in colorectal cancer metastasis. ACS Appl Bio Mater. 2023.
8.
Mukherjee, S., et al., Exosomal miRNAs and breast cancer: a complex theranostics interlink with clinical significance. Biomarkers. 2023. 1–17.
9.
Mathivanan, S., et al., ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res, 2012. 40(Database issue): pp D1241–4.
10.
11.
12.
Dhar R, Devi A, Patil S, Tovani-Palone MR. Exosomes in cancer therapy: advances and current challenges. Electron J Gen Med. 2023;20(5):em524.CrossRef
13.
14.
15.
Saleem SN, Abdel-Mageed AB. Tumor-derived exosomes in oncogenic reprogramming and cancer progression. Cell Mol Life Sci. 2015;72(1):1–10.PubMedCrossRef
16.
Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.PubMedCrossRef
17.
18.
Bhattacharya B, et al. Exosome DNA: An untold story of cancer. Clin Transl Disc. 2023;3: e218.CrossRef
19.
Shivji GG, et al. Role of exosomes and its emerging therapeutic applications in the pathophysiology of non-infectious diseases. Biomarkers. 2022;27(6):534–48.PubMedCrossRef
20.
Abels ER, Breakefield XO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol Neurobiol. 2016;36(3):301–12.PubMedPubMedCentralCrossRef
21.
Tricarico C, Clancy J, D’Souza-Schorey C. Biology and biogenesis of shed microvesicles. Small GTPases. 2017;8(4):220–32.PubMedCrossRef
22.
Guo X, Tan W, Wang C. The emerging roles of exosomal circRNAs in diseases. Clin Transl Oncol. 2021;23(6):1020–33.PubMedCrossRef
23.
Dhar R, et al. Exosome and epithelial–mesenchymal transition: a complex secret of cancer progression. J Cell Mol Med. 2023.
24.
Miller IV, Grunewald TG. Tumour-derived exosomes: tiny envelopes for big stories. Biol Cell. 2015;107(9):287–305.PubMedCrossRef
25.
26.
Jabbari N, et al. Tumor-derived extracellular vesicles: insights into bystander effects of exosomes after irradiation. Lasers Med Sci. 2020;35(3):531–45.PubMedCrossRef
27.
Jafari A, et al. Exosomes and cancer: from molecular mechanisms to clinical applications. Med Oncol. 2021;38(4):45.PubMedCrossRef
28.
29.
Meehan K, Vella LJ. The contribution of tumour-derived exosomes to the hallmarks of cancer. Crit Rev Clin Lab Sci. 2016;53(2):121–31.PubMedCrossRef
30.
31.
32.
Fontana S, et al. Contribution of proteomics to understanding the role of tumor-derived exosomes in cancer progression: state of the art and new perspectives. Proteomics. 2013;13(10–11):1581–94.PubMed
33.
Rak J, Guha A. Extracellular vesicles–vehicles that spread cancer genes. BioEssays. 2012;34(6):489–97.PubMedCrossRef
34.
35.
Niu L, et al. Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer. Cancer Sci. 2019;110(1):433–42.PubMedCrossRef
36.
Sharma S, et al. Tumor-derived exosomes in ovarian cancer - liquid biopsies for early detection and real-time monitoring of cancer progression. Oncotarget. 2017;8(61):104687–703.PubMedPubMedCentralCrossRef
37.
Pashoutan Sarvar, D., K. Shamsasenjan, and P. Akbarzadehlaleh, Mesenchymal Stem Cell-Derived Exosomes: New Opportunity in Cell-Free Therapy. Adv Pharm Bull, 2016. 6(3): 293–299.
38.
39.
Kharaziha P, et al. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta. 2012;1826(1):103–11.PubMed
40.
41.
Mathieu M, et al. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17.PubMedCrossRef
42.
Admyre C, et al. Exosomes with immune modulatory features are present in human breast milk. J Immunol. 2007;179(3):1969–78.PubMedCrossRef
43.
44.
Cheng H, et al. The tumor microenvironment shapes the molecular characteristics of exhausted CD8(+) T cells. Cancer Lett. 2021;506:55–66.PubMedCrossRef
45.
Whiteside, T.L., B. Diergaarde, and C.S. Hong, Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology. Int J Mol Sci, 2021. 22(12).
46.
47.
48.
Naito Y, et al. How cancer cells dictate their microenvironment: present roles of extracellular vesicles. Cell Mol Life Sci. 2017;74(4):697–713.PubMedCrossRef
49.
50.
Malla RR, Shailender G, Kamal MA. Exosomes: critical mediators of tumour microenvironment reprogramming. Curr Med Chem. 2021;28(39):8182–202.PubMedCrossRef
51.
Lan J, et al. M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Cancer Res. 2019;79(1):146–58.PubMedCrossRef
52.
Milane L, et al. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015;219:278–94.PubMedCrossRef
53.
54.
55.
Kara-Terki L et al. Critical Roles of Tumor Extracellular Vesicles in the Microenvironment of Thoracic Cancers. Int J Mol Sci, 2020. 21(17).
56.
57.
Desage AL et al. The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review. Cancers (Basel), 2021. 13(13)
58.
59.
Whiteside TL. Exosomes in cancer: another mechanism of tumor-induced immune suppression. Adv Exp Med Biol. 2017;1036:81–9.PubMedCrossRef
60.
61.
Maji S, et al. Exosomal Annexin II promotes angiogenesis and breast cancer metastasis. Mol Cancer Res. 2017;15(1):93–105.PubMedCrossRef
62.
63.
64.
Ying X, et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016;7(28):43076–87.PubMedPubMedCentralCrossRef
65.
Worbs T, Hammerschmidt SI, Forster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17(1):30–48.PubMedCrossRef
66.
Yu S, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007;178(11):6867–75.PubMedCrossRef
67.
Zhou M, et al. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Cell Immunol. 2014;292(1–2):65–9.PubMedCrossRef
68.
69.
Reiners KS, et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood. 2013;121(18):3658–65.PubMedPubMedCentralCrossRef
70.
Garcia-Iglesias T, et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer. 2009;9:186.PubMedPubMedCentralCrossRef
71.
Clayton A, et al. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008;180(11):7249–58.PubMedCrossRef
72.
Szczepanski MJ, et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 2011;96(9):1302–9.PubMedPubMedCentralCrossRef
73.
Berchem G, et al. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-beta and miR23a transfer. Oncoimmunology. 2016;5(4): e1062968.PubMedCrossRef
74.
Ye L, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J Immunother Cancer. 2018;6(1):145.PubMedPubMedCentralCrossRef
75.
Schroeder JC et al. Circulating exosomes inhibit b cell proliferation and activity. Cancers (Basel), 2020. 12(8)
76.
77.
Mao Y, et al. Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD-1(high) Breg cells. Cancer Sci. 2019;110(9):2700–10.PubMedPubMedCentralCrossRef
78.
Wieckowski EU, et al. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009;183(6):3720–30.PubMedCrossRef
79.
Montes CL, et al. Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res. 2008;68(3):870–9.PubMedCrossRef
80.
Zhang Y, et al. Interleukin-7 inhibits tumor-induced CD27-CD28- suppressor T cells: implications for cancer immunotherapy. Clin Cancer Res. 2011;17(15):4975–86.PubMedPubMedCentralCrossRef
81.
82.
Siegel RM, et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 2000;1(6):469–74.CrossRef
83.
Kim JW, et al. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010–20.PubMedCrossRef
84.
Abusamra AJ, et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis. 2005;35(2):169–73.PubMedCrossRef
85.
Contini P, et al. Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and Calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation. J Immunol. 2005;175(11):7244–54.PubMedCrossRef
86.
87.
Del Re M, et al. PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. Br J Cancer. 2018;118(6):820–4.PubMedPubMedCentralCrossRef
88.
Theodoraki MN, et al. Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24(4):896–905.PubMedCrossRef
89.
Mincheva-Nilsson L, Baranov V. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance. Semin Cancer Biol. 2014;28:24–30.PubMedCrossRef
90.
Skog J, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–6.PubMedPubMedCentralCrossRef
91.
Balaj L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011;2:180.PubMedCrossRef
92.
Ye SB, et al. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014;5(14):5439–52.PubMedPubMedCentralCrossRef
93.
94.
95.
Diao J, et al. Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3. Med Oncol. 2015;32(2):453.PubMedCrossRef
96.
Gobbo J et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. J Natl Cancer Inst; 2016. 108(3)
97.
98.
99.
100.
Roma-Rodrigues C, et al. Smuggling gold nanoparticles across cell types—a new role for exosomes in gene silencing. Nanomedicine. 2017;13(4):1389–98.PubMedCrossRef
101.
Sung BH, et al. Directional cell movement through tissues is controlled by exosome secretion. Nat Commun. 2015;6:7164.PubMedCrossRef
102.
Koumangoye RB, et al. Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PLoS ONE. 2011;6(9): e24234.PubMedPubMedCentralCrossRef
103.
104.
Luga V, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151(7):1542–56.PubMedCrossRef
105.
Paolillo M, Schinelli S Integrins and exosomes, a dangerous liaison in cancer progression. Cancers (Basel), 2017. 9(8)
106.
Bai S, et al. Role of tumour-derived exosomes in metastasis. Biomed Pharmacother. 2022;147: 112657.PubMedCrossRef
107.
Webber J, et al. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010;70(23):9621–30.PubMedCrossRef
108.
Zhang Q, Peng C. Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer. Oncol Lett. 2018;15(1):691–8.PubMed
109.
110.
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.PubMedCrossRef
111.
Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008;5(4):194–204.PubMedCrossRef
112.
Momeny M, et al. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Sci Rep. 2017;7:45954.PubMedPubMedCentralCrossRef
113.
Katoh M. Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med. 2013;32(4):763–7.PubMedPubMedCentralCrossRef
114.
115.
Gesierich S et al. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res, 2006; 66(14): 7083–94.
116.
117.
118.
Syn N, et al. Exosome-mediated metastasis: from epithelial-mesenchymal transition to escape from immunosurveillance. Trends Pharmacol Sci. 2016;37(7):606–17.PubMedCrossRef
119.
Sanchez CA, et al. Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 2016;7(4):3993–4008.PubMedCrossRef
120.
Dhar R et al. Exosomal microRNAs (exoMIRs): micromolecules with macro impact in oral cancer. 3 Biotech. 2022(12):155.
121.
Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta. 2009;1796(2):293–308.PubMed
122.
123.
124.
Whiteside TL. The role of tumor-derived exosomes in epithelial mesenchymal transition (EMT). Transl Cancer Res. 2017;6(Suppl 1):S90–2.CrossRef
125.
Wang X, et al. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kgamma to promote pancreatic cancer metastasis. Cancer Res. 2018;78(16):4586–98.CrossRef
126.
127.
Dhar R et al. Interrelation between extracellular vesicles miRNAs with chronic lung diseases. J Cell Physiol, 237(11):4021–4036.
128.
129.
130.
Ferlay J et al. Cancer statistics for the year 2020: an overview. Int J Cancer, 2021.
131.
132.
133.
Seijo LM, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol. 2019;14(3):343–57.PubMedCrossRef
134.
Cheng N, et al. Recent advances in biosensors for detecting cancer-derived exosomes. Trends Biotechnol. 2019;37(11):1236–54.PubMedCrossRef
135.
Gowri A, Ashwin Kumar N, Suresh Anand BS, Recent advances in nanomaterials based biosensors for point of care (PoC) diagnosis of Covid-19—a minireview. Trends Analyt Chem, 2021;137: 116205.
136.
Sardini E, Serpelloni M, Tonello S, Printed electrochemical biosensors: opportunities and metrological challenges. Biosensors (Basel), 2020. 10(11).
137.
Moss JL, et al. Persistent poverty and cancer mortality rates: an analysis of county-level poverty designations. Cancer Epidemiol Biomarkers Prev. 2020;29(10):1949–54.PubMedPubMedCentralCrossRef
138.
Yoshida K, et al. Exploring designability of electrostatic complementarity at an antigen-antibody interface directed by mutagenesis, biophysical analysis, and molecular dynamics simulations. Sci Rep. 2019;9(1):4482.PubMedPubMedCentralCrossRef
139.
Xia Y, et al. A visible and colorimetric aptasensor based on DNA-capped single-walled carbon nanotubes for detection of exosomes. Biosens Bioelectron. 2017;92:8–15.PubMedCrossRef
140.
Oliveira-Rodriguez M, et al. Development of a rapid lateral flow immunoassay test for detection of exosomes previously enriched from cell culture medium and body fluids. J Extracell Vesicles. 2016;5:31803.PubMedCrossRef
141.
Chen X, et al. A paper-supported aptasensor based on upconversion luminescence resonance energy transfer for the accessible determination of exosomes. Biosens Bioelectron. 2018;102:582–8.PubMedCrossRef
142.
He F, et al. Quantification of exosome based on a copper-mediated signal amplification strategy. Anal Chem. 2018;90(13):8072–9.PubMedCrossRef
143.
144.
Sina AA, et al. Label-free detection of exosomes using a surface plasmon resonance biosensor. Anal Bioanal Chem. 2019;411(7):1311–8.PubMedCrossRef
145.
Kwizera EA, et al. Molecular detection and analysis of exosomes using surface-enhanced raman scattering gold nanorods and a miniaturized device. Theranostics. 2018;8(10):2722–38.PubMedPubMedCentralCrossRef
146.
Zong S, et al. SERS-fluorescence-superresolution triple-mode nanoprobe based on surface enhanced Raman scattering and surface enhanced fluorescence. J Mater Chem B. 2020;8(36):8459–66.PubMedCrossRef
147.
Wang Z, et al. Screening and multiple detection of cancer exosomes using an SERS-based method. Nanoscale. 2018;10(19):9053–62.PubMedCrossRef
148.
Park J, et al. An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma. Nat Biomed Eng. 2021;5(7):678–89.PubMedPubMedCentralCrossRef
149.
Song D, et al. Sandwich-type electrochemical immunosensor for CEA detection using magnetic hollow Ni/C@SiO(2) nanomatrix and boronic acid functionalized CPS@PANI@Au probe. Talanta. 2021;225: 122006.PubMedCrossRef
150.
Wang S, et al. Aptasensor with expanded nucleotide using dna nanotetrahedra for electrochemical detection of cancerous exosomes. ACS Nano. 2017;11(4):3943–9.PubMedPubMedCentralCrossRef
151.
Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013;32(3–4):623–42.PubMedCrossRef
152.
Rahbarghazi R, et al. Tumor-derived extracellular vesicles: reliable tools for Cancer diagnosis and clinical applications. Cell Commun Signal. 2019;17(1):73.PubMedPubMedCentralCrossRef
153.
154.
Filipazzi P, et al. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol. 2012;22(4):342–9.PubMedCrossRef
155.
Sun Y, Liu J. Potential of cancer cell-derived exosomes in clinical application: a review of recent research advances. Clin Ther. 2014;36(6):863–72.PubMedCrossRef
156.
Langevin S, et al. Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells in vitro reveals common secretion profiles and potential utility as salivary biomarkers. Oncotarget. 2017;8(47):82459–74.PubMedPubMedCentralCrossRef
157.
158.
An T, et al. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J Extracell Vesicles. 2015;4:27522.PubMedCrossRef
159.
Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75–93.PubMedCrossRef
160.
Liao J, et al. Exosome-shuttling microRNA-21 promotes cell migration and invasion-targeting PDCD4 in esophageal cancer. Int J Oncol. 2016;48(6):2567–79.PubMedCrossRef
161.
162.
Krishnan A, et al. Salivary exosomes: a theranostics secret of oral cancer—correspondence. Int J Surg. 2022;108: 106990.PubMedCrossRef
163.
Tanaka Y, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2013;119(6):1159–67.PubMedCrossRef
164.
165.
Ghorbanmehr N, et al. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. Prostate. 2019;79(1):88–95.PubMedCrossRef
166.
Lin H, et al. Urinary exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer. BMC Cancer. 2021;21(1):1293.PubMedPubMedCentralCrossRef
167.
Josson S, et al. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene. 2015;34(21):2690–9.PubMedCrossRef
168.
Wolfers J, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7(3):297–303.PubMedCrossRef
169.
Verdi J, et al. Development and clinical application of tumor-derived exosomes in patients with cancer. Curr Stem Cell Res Ther. 2022;17(1):91–102.PubMedCrossRef
170.
Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–21.PubMedCrossRef
171.
Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.PubMedPubMedCentralCrossRef
172.
Alsaab HO, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.PubMedPubMedCentralCrossRef
173.
Cheng L, et al. Exosomes from melatonin treated hepatocellularcarcinoma cells alter the immunosupression status through STAT3 pathway in macrophages. Int J Biol Sci. 2017;13(6):723–34.PubMedPubMedCentralCrossRef
174.
175.
Hou W, et al. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Invest New Drugs. 2019;37(5):876–89.PubMedCrossRef
176.
177.
Gao J, et al. Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer. Biochem Biophys Res Commun. 2018;498(3):409–15.PubMedCrossRef
178.
Gu X, et al. Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int J Cancer. 2015;136(4):E74-84.PubMedCrossRef
179.
Rezaei R, et al. Tumor-derived exosomes enriched by miRNA-124 promote anti-tumor immune response in CT-26 tumor-bearing mice. Front Med (Lausanne). 2021;8: 619939.PubMedPubMedCentralCrossRef
180.
Batista IA, Melo SA Exosomes and the future of immunotherapy in pancreatic cancer. Int J Mol Sci, 2019. 20(3)
181.
182.
Dhar R, et al. Exosome-based cancer vaccine: a cutting-edge approach—correspondence. Int J Surg. 2022;108: 106993.PubMedCrossRef
183.
Chen YS, et al. Exosomes in clinical trial and their production in compliance with good manufacturing practice. Ci Ji Yi Xue Za Zhi. 2019;32(2):113–20.PubMed
184.
185.
Huang Y, et al. Exosomes function in tumor immune microenvironment. Adv Exp Med Biol. 2018;1056:109–22.PubMedCrossRef
186.
Rezaie J, Feghhi M, Etemadi T. A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal. 2022;20(1):145.PubMedPubMedCentralCrossRef
187.
188.
Brinton LT, et al. Formation and role of exosomes in cancer. Cell Mol Life Sci. 2015;72(4):659–71.PubMedCrossRef
189.
190.
Dhar R et al. Decoding of exosome heterogeneity for cancer theranostics. Clin Transl Med. 2023;e1288.
191.
Gould SJ, Raposo G As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles, 2013. 2
192.
193.
Harding C, et al. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 1983;97(2):329–39.PubMedCrossRef
194.
Martins VR, et al. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol. 2013;25(1):66–75.PubMedCrossRef
195.
Kar R, et al, Exosome-based smart drug delivery tool for cancer theranostics. ACS Biomater Sci Eng. 2023.
196.
Wilson DH, et al. The simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J Lab Autom. 2016;21(4):533–47.PubMedCrossRef
197.
Dhar R, et al. Exosome: a megastar of future cancer personalized and precision medicine. Clin Transl Disc. 2023;3: e208.CrossRef
198.
Huda MN, et al. Potential use of exosomes as diagnostic biomarkers and in targeted drug delivery: progress in clinical and preclinical applications. ACS Biomater Sci Eng. 2021;7(6):2106–49.PubMedPubMedCentralCrossRef
Metadata
Title
Theranostic signature of tumor-derived exosomes in cancer
Authors
Samruti Kumar
Rajib Dhar
Lokesh Babu Sirkali Suresh Kumar
Gauresh Gurudas Shivji
Rama Jayaraj
Arikketh Devi
Publication date
01-11-2023
Publisher
Springer US
Published in
Medical Oncology / Issue 11/2023
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-023-02176-6

Other articles of this Issue 11/2023

Medical Oncology 11/2023 Go to the issue

Review Article

How gallic acid regulates molecular signaling: role in cancer drug resistance

Original Paper

Musashi-2 (MSI2) promotes neuroblastoma tumorigenesis through targeting MYC-mediated glucose-6-phosphate dehydrogenase (G6PD) transcriptional activation

Original Paper

Colorectal cancer cell membrane biomimetic ferroferric oxide nanomaterials for homologous bio-imaging and chemotherapy application

Original Paper

Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the AblT315I mutant kinase to combat imatinib resistance in chronic myeloid leukemia

Review Article

Himalayan flora: targeting various molecular pathways in lung cancer

Review Article

Involving stemness factors to improve CAR T-cell-based cancer immunotherapy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits